Monitored issues related to the regulation of pharmacogenomic tests.
Monitored issues related to laboratory developed tests and reimbursement. Monitored implementation of P.L. 117-2, the American Rescue Plan.
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID-19 testing and provider relief.
Issues related to access to depression treatments for veterans. Monitored implementation of P.L. 116-171, Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019.
Issues related to access to depression treatments for veterans.
Duration: August 19, 2019
to
June 30, 2021
General Issues: Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Health Issues , Veterans , Budget/Appropriations
Spending: about $380,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Office of Management & Budget (OMB)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stacey Hughes
U.S. Senate Budget Cmte, Dpty Staff Dir;Ofce of the Asst. Maj. Ldr (Sen. Nickles), Policy Adv; Office of the Asst. Min. Ldr (Sen. Nickles), Policy Adv.;Senate Spec. Cmte on Aging (Sen.Cohen),Prof. Staff Member; U.S.Sen Connie Mack, Leg Asst/Schdlr
Emily Porter
Ofce of Spkr(Rep.Boehner),Asst to Spkr,Policy;Ofce of Min. Ldr(Rep.Boehner),Plcy Adv;Ofce of the Maj. Ldr(Rep. Boehner),Plcy Adv;Cmte Ed & the Wrkfrc(Rep.Boehner),Coalitions Dir. for Educ Plcy; Rep.Trent Franks,Sr.Leg.Asst; Rep.Tom Tancredo,Leg.Asst
Mary Beth Savary Taylor
Joint Economic Committee, General Counsel; U.S. Senator Connie Mack, Legislative Assistant
Jeff Choudhry
U.S. Rep. Trent Franks, Legislative Director; U.S. Rep. Trent Franks, Legislative Assistant / Staff Assistant; House Small Business Committee, Intern
Stephanie Badger
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2021
THE NICKLES GROUP, LLC terminated an engagement in which they represented Myriad Genetics, Inc. on July 19, 2021.
Original Filing: 301283597.xml
Lobbying Issues
Monitored issues related to the regulation of pharmacogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Monitored issues related to laboratory developed tests and reimbursement. Monitored implementation of P.L. 117-2, the American Rescue Plan.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID-19 testing and provider relief.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to access to depression treatments for veterans. Monitored implementation of P.L. 116-171, Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to access to depression treatments for veterans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301262340.xml
Lobbying Issues
Monitored issues related to the regulation of pharmacogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Monitored issues related to laboratory developed tests and reimbursement. Monitored P.L. 117-2, the American Rescue Plan.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitored P.L. 117-2, the American Rescue Plan, as it relates to COVID-19 testing and provider relief.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to access to depression treatments for veterans. Issues related to implementation of P.L. 116-171, Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to access to depression treatments for veterans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301242632.xml
Lobbying Issues
S 3404, VALID Act and regulation of pharmacogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to laboratory developed tests and reimbursement; issues related to the implementation of P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to the 2020 OPPS rule specifically related to packaging policy. Monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021, as it relates to surprise medical billing. Issues related to provider relief fund.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to S. 3404, VALID Act. Monitored issues related to the implementation of P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to S. 1895, the Lower Healthcare Cost Act including Surprise Medical Billing, issues related to H.R. 861, the End Surprise Billing Act, H.R. 5800, The Ban Surprise Billing Act; issues related to EKRA; H.R. 925 / H.R. 8406, The HEROES Act, issues related to COVID-19 testing and provider relief. H.R. 133, the Consolidated Appropriations Act of 2021, including surprise medical bill and COVID-19 testing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to access for veterans to pharmacogenomic testing for mental health. Issues related to implementation of S. 785, Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301213046.xml
Lobbying Issues
S 3404, VALID Act and regulation of pharmcogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to laboratory developed tests and reimbursement; issues related to the implementation of P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to S. 3404, VALID Act. Monitored issues related to the implementation of P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to S. 1895, the Lower Healthcare Cost Act including Surprise Medical Billing, issues related to H.R. 861, the End Surprise Billing Act, H.R. 5800, The Ban Surprise Billing Act; issues related to EKRA; H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act, issues related to COVID-19 testing and provider relief.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2020
In Q2, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301196244.xml
Lobbying Issues
S 3404, VALID Act and regulation of pharmcogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to laboratory developed tests and reimbursement; issues related to the implementation of P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to S. 3404, VALID Act. Monitored issues related to the implementation of P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to S. 1895, the Lower Healthcare Cost Act including Surprise Medical Billing, issues related to H.R. 861, the End Surprise Billing Act, H.R. 5800, The Ban Surprise Billing Act; issues related to EKRA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2020
In Q1, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301171186.xml
Lobbying Issues
Issues related to regulation of pharmcogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to laboratory developed tests and reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to the VALID Act. P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to S. 1895, the Lower Healthcare Cost Act including Surprise Medical Billing, issues related to H.R. 861, the End Surprise Billing Act, H.R. 5800, The Ban Surprise Billing Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301125375.xml
Lobbying Issues
Issues related to regulation of pharmcogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Executive Office of the President (EOP)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to laboratory developed tests and reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to the VALID Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, THE NICKLES GROUP, LLC lobbied for Myriad Genetics, Inc. , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301074362.xml
Lobbying Issues
Issues related to regulation of pharmcogenomic tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Executive Office of the President (EOP)
Type of Issue
Medical/Disease Research/Clinical Labs
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate